Abbott Laboratories $ABT Shares Bought by Northside Capital Management LLC

Key Points

• Northside Capital Management LLC significantly increased its stake in Abbott Laboratories by 97.9%, acquiring an additional 3,820 shares, bringing its total holdings to 7,720 shares valued at $1,050,000.
• Abbott Laboratories reported a quarterly EPS of $1.26, matching analyst expectations, with a year-over-year revenue increase of 7.4% to $11.14 billion.
• The company recently announced a quarterly dividend of $0.59 per share, with an annualized yield of 1.7%, set to be paid on November 17th.

Northside Capital Management LLC boosted its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 97.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,720 shares of the healthcare product maker's stock after buying an additional 3,820 shares during the period. Northside Capital Management LLC's holdings in Abbott Laboratories were worth $1,050,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. IMS Capital Management acquired a new position in Abbott Laboratories during the second quarter worth approximately $1,225,000. Graypoint LLC increased its position in Abbott Laboratories by 0.3% during the second quarter. Graypoint LLC now owns 42,999 shares of the healthcare product maker's stock worth $5,848,000 after buying an additional 110 shares during the period. Financial Management Professionals Inc. increased its position in Abbott Laboratories by 715.7% during the second quarter. Financial Management Professionals Inc. now owns 6,142 shares of the healthcare product maker's stock worth $835,000 after buying an additional 5,389 shares during the period. Sara Bay Financial increased its holdings in shares of Abbott Laboratories by 21.2% in the second quarter. Sara Bay Financial now owns 10,198 shares of the healthcare product maker's stock valued at $1,387,000 after purchasing an additional 1,782 shares during the period. Finally, Ballentine Partners LLC increased its holdings in shares of Abbott Laboratories by 5.5% in the second quarter. Ballentine Partners LLC now owns 53,498 shares of the healthcare product maker's stock valued at $7,276,000 after purchasing an additional 2,771 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Trading Down 0.6%

Shares of ABT stock opened at $135.82 on Wednesday. The business's fifty day moving average price is $130.65 and its 200 day moving average price is $131.15. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The firm has a market capitalization of $236.39 billion, a PE ratio of 17.02, a P/E/G ratio of 2.59 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories's quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's payout ratio is presently 29.57%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Evercore ISI boosted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Leerink Partners assumed coverage on Abbott Laboratories in a report on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price on the stock. BTIG Research dropped their target price on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. William Blair raised Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Finally, Mizuho boosted their target price on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $145.22.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.